Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]
Status Suspended
Decision Selected
Process STA pre-2018
Referral date 01 November 2011
Topic area
  • Cancer
  • Urogenital

Scoped within Batch 20.

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: Alice Law
Executive Lead: TBC
Project manager:

Lori Farrar

Technical Lead: Richard Diaz


Key events during the development of the guidance:

Date Update
28 November 2013

The Institute has now been informed by the manufacturer that it will no longer be pursuing a licensing application for denosumab in this indication, therefore, NICE has decided to suspend this appraisal on its current work programme.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

17 April 2013 The manufacturer of Denosumab has informed NICE that they will not provide a submission for this appraisal. NICE has therefore suspended this appraisal.

For further information on our processes and methods, please see our CHTE processes and methods manual